NATCO Pharma Schedules Q4FY26 Earnings Call on May 29

NATCO Pharma has announced it will host an earnings call to discuss the audited financial results for the quarter and year ended March 31, 2026. The conference call is scheduled for Friday, May 29, 2026, at 16:30 PM IST. The announcement follows the company's intimation regarding its Board of Directors meeting convened to consider and approve the said financial results.

Earnings Call Details

The earnings call will be hosted by 360 ONE Capital Market Private Limited. Key management personnel from NATCO Pharma will participate, including Mr. Rajeev Nannapaneni, Vice-chairman and CEO; Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences; and Mr. Amit Parekh, Chief Financial Officer (CFO).

Parameter	Details
Date & Time	Friday, May 29, 2026 at 16:30 PM IST
Purpose	Discussion of Q4 and FY26 Audited Financial Results
Host	360 ONE Capital Market Private Limited

Conference Dial-in Information

Investors and analysts can join the call using the following access numbers:

Country	Access Number
India (Mumbai)	+91 22 6280 1222, +91 22 7115 8123
USA	18667462133
UK	08081011573
Singapore	8001012045
Japan	00531161110

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities is closed from May 19, 2026. The window will reopen 48 hours after the declaration of the financial results. This restriction applies to employees, connected persons, and their immediate relatives to ensure adherence to insider trading norms.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.56%	+0.20%	+6.75%	+35.09%	+37.83%	+25.66%

NATCO Pharma Limited has disclosed the receipt of a demand notice from the National Pharmaceutical Pricing Authority (NPPA), New Delhi, dated 12th May, 2026. The disclosure was made by Ch. Venkat Ramesh, Company Secretary and Compliance Officer, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 updated on January 30, 2026.

Demand Notice Details

The demand notice was issued under para 15 of the Drugs Price Control Order, 2013 (DPCO), directing NATCO Pharma to deposit a total amount of ₹4,92,25,923, which comprises the overcharge amount, penalty, and interest. The notice alleges overcharging for 2 drugs covering the period between April 2023 to November 2023. The following table summarises the key details of the regulatory action as disclosed by the company:

Parameter:	Details
Authority:	National Pharmaceutical Pricing Authority, New Delhi
Nature of Action:	Demand Notice under para 15 of Drugs Price Control Order, 2013 (DPCO)
Amount Demanded:	₹4,92,25,923 (includes overcharge amount, penalty and interest)
Date of Demand Notice:	12th May, 2026
Date of Receipt:	12th May, 2026
Alleged Violation:	Overcharging for 2 drugs
Period of Alleged Overcharging:	April 2023 to November 2023
Financial Impact:	No material impact on financial, operational, and other activities

Disclosure Delay

In its updated filing dated 15th May, 2026, NATCO Pharma acknowledged a delay in the submission of the initial disclosure, attributing it to technical issues and procedural delays in the flow of information. The company confirmed that it has since complied with the disclosure requirements under SEBI (LODR) Regulations, 2015 and submitted the necessary information to the stock exchanges. NATCO Pharma also stated that it shall take necessary steps to avoid recurrence of such delays in future.

Company's Assessment of Impact

NATCO Pharma has stated that the demand notice has no material impact on the financial, operational, or other activities of the company. The disclosure was made in accordance with applicable regulatory requirements under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.